A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis

NCT01497119 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

88

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated prematurely due to 2 cases of agranulocytosis.

Conditions

Dermatitis, Atopic

Interventions

DRUG: JNJ-39758979, 300 mg
DRUG: JNJ-39758979, 100 mg
DRUG: Placebo

Sponsor

Janssen Pharmaceutical K.K.